Acute cardiac care & resuscitation
IL-17A monoclonal antibody as a translational therapy for post-cardiac arrest brain injury: clinical and preclinical evidence
Main finding · Serum IL-17A 24 h post-ROSC and poor neurological outcome (CPC 3-5) at 30 daysResult — go to the resultAdjusted odds ratio 3.56 95 % CI 1.31–9.63Authors' conclusion
Elevated serum IL-17A is a potential early predictor of poor outcomes in PCABI. Early administration of anti-IL-17A mAb improved neurological recovery and survival in the experimental CA model by attenuating neuroinflammation.
Study context
- Population
- Adult cardiac arrest (CA) patients with return of spontaneous circulation (ROSC); rat asphyxial CA model
- Exposure
- Anti-IL-17A mAb vs vehicle in a rat asphyxial CA model
- CAn = 80
- Controlsn = 10reference
- Outcome
- Poor neurological outcome (CPC 3-5) predicted by serum IL-17A at 24 h post-ROSC
- Follow-up
- 30 days
Main finding
As reported in the abstract
Serum IL-17A 24 h post-ROSC and poor neurological outcome (CPC 3-5) at 30 days
Adjusted odds ratio
3.56
95 % CI 1.31–9.63
By group
IL-17A
adjusted OR 3.56 (95 % CI 1.31–9.63)
- AUC of IL-17A for predicting neurological dysfunction
- 0.702
Observational data: associations, not effects.
Further findings
| Outcome | CA | Controls | Anti-IL-17A mAb | Vehicle | |
|---|---|---|---|---|---|
| Serum IL-17A, CA patients vs controls · 24 h post-ROSC | 2.42 ± 1.25 pg/mL | Not reported in the abstract | Not reported in the abstract | Not reported in the abstract | Controls, Anti-IL-17A mAb, Vehicle: not reported in the abstract |
| 11-day survival (rats) | Not reported in the abstract | Not reported in the abstract | 62.5 % | 30.3 % | CA, Controls: not reported in the abstract |
- Serum IL-17A, CA patients vs controls: p < 0.001
11-day survival (rats)
- Improved neurological scores and Morris water maze performance with anti-IL-17A mAb
- Reduced TNF-α, NSE and NfL in serum and brain tissue with anti-IL-17A mAb
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
IL-17A monoclonal antibody as a translational therapy for post-cardiac arrest brain injury: clinical and preclinical evidence. Resuscitation. Published 30 October 2025. doi:10.
Summarised from the published abstract; every number is checked against it